{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elbasvir",
    "query": {
      "intervention": "Elbasvir"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 22,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elbasvir&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T03:21:55.669Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01797536",
      "title": "The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Insufficiency"
      ],
      "interventions": [
        {
          "name": "Elbasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 31,
      "start_date": "2013-03-06",
      "completion_date": "2014-08-20",
      "has_results": true,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01797536"
    },
    {
      "nct_id": "NCT03093740",
      "title": "Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Failure Chronic",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Zepatier",
          "type": "DRUG"
        },
        {
          "name": "Zepatier plus Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 0,
      "start_date": "2018-10-01",
      "completion_date": "2021-01-31",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03093740"
    },
    {
      "nct_id": "NCT02902120",
      "title": "HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C",
        "Renal Insufficiency, Chronic",
        "Disorder of Transplanted Kidney"
      ],
      "interventions": [
        {
          "name": "Post-transplant Grazoprevir and Elbasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Maryland, Baltimore",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2017-05-01",
      "completion_date": "2022-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02902120"
    },
    {
      "nct_id": "NCT02945150",
      "title": "Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 8,
      "start_date": "2017-02-01",
      "completion_date": "2020-03-05",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02945150"
    },
    {
      "nct_id": "NCT02940496",
      "title": "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCLC Stage B Hepatocellular Carcinoma",
        "BCLC Stage C Hepatocellular Carcinoma",
        "Hepatitis C Infection",
        "Refractory Liver Carcinoma",
        "Stage III Hepatocellular Carcinoma AJCC v7",
        "Stage IIIA Hepatocellular Carcinoma AJCC v7",
        "Stage IIIB Hepatocellular Carcinoma AJCC v7",
        "Stage IIIC Hepatocellular Carcinoma AJCC v7",
        "Stage IV Hepatocellular Carcinoma AJCC v7",
        "Stage IVA Hepatocellular Carcinoma AJCC v7",
        "Stage IVB Hepatocellular Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Elbasvir/Grazoprevir",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2016-12-09",
      "completion_date": "2023-08-09",
      "has_results": true,
      "last_update_posted_date": "2025-07-15",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02940496"
    },
    {
      "nct_id": "NCT03127358",
      "title": "Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C",
        "Medication Adherence"
      ],
      "interventions": [
        {
          "name": "AiCure",
          "type": "DEVICE"
        },
        {
          "name": "AiCure with gamification",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2017-11-14",
      "completion_date": "2019-02-06",
      "has_results": true,
      "last_update_posted_date": "2021-09-14",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03127358"
    },
    {
      "nct_id": "NCT03585101",
      "title": "A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Elbasvir/grazoprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-08",
      "completion_date": "2020-04",
      "has_results": false,
      "last_update_posted_date": "2018-08-07",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03585101"
    },
    {
      "nct_id": "NCT02786537",
      "title": "Study of Oral Treatments for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SOF/LDV (sofosbuvir/ledipasvir)",
          "type": "DRUG"
        },
        {
          "name": "PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only)",
          "type": "DRUG"
        },
        {
          "name": "EBR/GZR (elbasvir/grazoprevir)",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1275,
      "start_date": "2016-06",
      "completion_date": "2020-09-02",
      "has_results": true,
      "last_update_posted_date": "2021-12-06",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 38,
      "location_summary": "Little Rock, Arkansas • Palo Alto, California • San Diego, California + 27 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02786537"
    },
    {
      "nct_id": "NCT03221582",
      "title": "Impact of Hepatitis C Therapy and Bone Health",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "EBR/GZR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dallas VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "40 Years and older · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2017-08-28",
      "completion_date": "2018-11-30",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03221582"
    },
    {
      "nct_id": "NCT02781649",
      "title": "Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End-Stage Renal Disease",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Zepatier",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-07-20",
      "completion_date": "2018-01-01",
      "has_results": true,
      "last_update_posted_date": "2018-09-06",
      "last_synced_at": "2026-10-29T03:21:55.669Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02781649"
    }
  ]
}